Stay updated with breaking news from Seqirus Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of...
/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the Biomedical Advanced Research...
Share this article Share this article SUMMIT, N.J., March 5, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX ® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older. 1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U...
Expert panel votes FDA SHOULD give Moderna's COVID-19 vaccine emergency approval amid hopes the U.S will soon have a second shot to help get 20 million Americans vaccinated by the end of 2020 A panel of FDA experts voted that the agency should approve Moderna's coronavirus vaccine and recommend whether the shot should be approved With their endorsement, Moderna's shot will almost certainly get emergency approval tonight or tomorrow Two people in Moderna's trial had severe allergic reactions: one who got a placebo, and a vaccine recipient who had anaphylactic shock 63 days later Modern...